Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Lymphoma

Lymphoproliferative Disorders

Hodgkin Disease

Lymphoma, Non-Hodgkin

Neoplasms by Histologic Type

Lymphatic Diseases

Immunoproliferative Disorders

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphosarcoma

Hodgkin Lymphoma

All Drugs and Chemicals

Lenograstim

Adjuvants, Immunologic

Immunologic Factors

lenograstim

This investigator initiated trial was a prospective, open, single-arm, diagnostic-prognostic study. Patients who received high-dose therapy with autologous stem cell transplantation for the treatment of their lymphoproliferative disease were included into the study.

After completion of the high-dose therapy (day -2 with respect to the stem cell transplantation) the first blood sample A for the cytocapacity test with determination of leukocytes and neutrophils was taken in the evening of day -1. Directly thereafter the study medication was administered. The second blood sample B for the cytocapacity test with determination of leukocytes and neutrophils was taken in the morning of day 0, 12-14 hours after administration of the study medication. Thereafter the stem cell re-infusion was performed.

The primary objective of this study was to show that the cytocapacity test with lenograstim is a useful predictive tool with respect to the risk of post-transplant complications and prolonged myelosuppression, typically occurring after high-dose chemotherapy.

The primary variables were:

* the rate of patients with documented infections
* the time to platelet engraftment

Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy

Predictive Value of the "Cytocapacity Test" Following a Single-dose of rHu-G-CSF in Patients With Lymphoproliferative Diseases and High-dose Therapy

Ludwig-Maximilians - University of Munich

Chugai Pharma GmbH

WiSP Wissenschaftlicher Service Pharma GmbH

Dr. Christian Straka

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy	NCT01085058	Hodgkin's Disea... Non-Hodgkin Lym... Multiple Myelom...	lenograstim	18 Years - 70 Years	WiSP Wissenschaftlicher Service Pharma GmbH
Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy	NCT01085058	Hodgkin's Disea... Non-Hodgkin Lym... Multiple Myelom...	lenograstim	18 Years - 70 Years	WiSP Wissenschaftlicher Service Pharma GmbH

Spots Global Cancer Trial Database for multiple myelomas